Table 1 Basic characteristics of included studies
From: Therapeutic effects of electrical stimulation on overactive bladder: a meta-analysis
Source | Chen et al. (2015) | McClurg et al. (2008) | Kajbafzadeh et al. (2014) | Kajbafzadeh et al. (2009) | Meng et al. (2015) | Yamanishi et al. (2000) | Chen et al. (2012) | Peters et al. (2009) | Peters et al. (2010) | Arruda et al. (2008) |
|---|---|---|---|---|---|---|---|---|---|---|
No. of patients (T/C) | 50/48 | 37/37 | 15/15 | 19/10 | 20/15 | 32/26 | 30/30 | 41/43 | 103/105 | 21/22 |
No. of female (%) (T/C) | 6/6 | 84/70 | 46/34 | 63/60 | Unknown | 62/52 | 37/43 | 96/92 | 78.2/80 | 100/100 |
Mean age, year (T/C) | 32.9 ± 1.8/ 33.5 ± 1.7 | 48.3 ± 11.5/ 52.0 ± 8.8 | 5.9 ± 3.5/ 7.4 ± 3.6 | 5.7 ± 2.8/ 5.6 ± 2.4 | 36 ± 8/ 36 ± 7 | 67.5 ± 12.7/ 73.0 ± 8.7 | 65.60 ± 3.79/ 61.93 ± 3.67 | 57.5 ± 15.2/ 58.2 ± 11.3 | 62.5/ 60.2 | 35–80 |
Duration of disease, years (T/C) | 3.5 ± 1.4/ 3.3 ± 1.7 | Unknown | Unknown | Unknown | 1.2 ± 0.7 | 4.7 ± 5.2/ 4.6 ± 8.0 | 5.4 ± 1.75 | 9.8 ± 12.3/ 9.4 ± 12.1 | 10.2 ± 11.5/ 9.8 ± 10.4 | Unknown |
Cause of OAB | SCI | MS | Myelomeningocele | Myelomeningocele | SCI | Unknown | PD | Unknown | Unknown | Unknown |
Design | RCT | RCT | RCT | RCT | RCT | RCT | RCT | RCT | RCT | RCT |
Intervention | T:PTNS C:solifenacin succinate (5 mg/d) | T:PFMT + EMG biofeedbock + active NMES C:PFMT + EMG biofeedbock + placebo NMES | T:FES C:sham stimulation | T:IFS C: sham stimulation | T:Electroacupuncture +BTX-A + Rehabilitation training C:BTX-A + Rehabilitation training | T:DP/CNS C:sham stimulation | T:Electroacupuncture + Tolterodine(1 mg twice a day) C:tolterodine(2 mg twice a day) | T:PTNS C:tolterodine(4 mg/d) | T:PTNS C:sham stimulation | T:FES C:PFMT |
Duration of the treatment | 4 weeks | 9 weeks | 15 courses | 2 weeks | 4 weeks | 4 weeks | 6 weeks | 12 weeks | 12 weeks | 12 weeks |
Outcome Measures | ①| ①④ | ①②③⑤ | ①②③④⑤ | ①②④ | ①②③ | ①| ①⑤ | ①⑤ | ①②⑤ |
Follow-up,weeks | 16.24 | 6 | 79 ± 5 | 38 |